OEZ Stock Chart & Stats
$0.01
<$0.01(9.09%)
At close: 4:00 PM EST
$0.01
<$0.01(9.09%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume4.00K
Average Volume (3M)N/A
Market Cap
€51.66M
Enterprise Value$33.92M
Total Cash (Recent Filing)€4.66M
Total Debt (Recent Filing)€14.47K
Price to Earnings (P/E)―
Beta9.68
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,863,725,800
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary TPM Drug‑delivery PlatformAvecho’s proprietary Tocopheryl Phosphate Mixture (TPM) is a durable technological asset that supports formulation advantages across pharmaceuticals and nutraceuticals. A platform model enables licensing, recurring royalties and partner development, fostering scalable, margin‑enhancing revenue streams over time.
2025 Revenue Growth And Cash‑flow TurnaroundThe swing to positive operating and free cash flow in 2025, alongside accelerating revenue, indicates improving unit economics and a reduced near‑term funding gap. Sustained cash generation would materially lower financing needs and support commercialization or partner investments over the medium term.
Low Leverage And Manageable DebtVery low reported debt provides financial flexibility to pursue licensing, partnerships or selective product launches without heavy interest burdens. This balance‑sheet posture reduces insolvency risk and preserves optionality for strategic investments or absorbing short‑term operational shocks.
Bears Say
Persistent Operating And Net LossesDespite revenue gains, recurring operating and net losses materially erode profitability and require ongoing capital or partner funding. Persistent negative earnings constrain the ability to build retained earnings, limit reinvestment capacity and raise long‑term sustainability concerns if losses persist.
Declining Equity / Value ErosionA meaningful decline in equity reduces the company’s financial buffer and borrowing capacity, increasing dilution risk when new capital is needed. Continued erosion of book value signals structural profitability issues and weakens resilience to adverse development or commercialization delays.
Small Scale And Resource ConstraintsA very small headcount and volatile cash flows imply limited internal capacity to execute complex clinical, regulatory or commercial programs. Resource constraints increase dependence on partners and heighten execution risk, making sustained growth and consistent cash generation harder to achieve.
Avecho Biotechnology Limited News
OEZ FAQ
What was Avecho Biotechnology Limited’s price range in the past 12 months?
Currently, no data Available
What is Avecho Biotechnology Limited’s market cap?
Avecho Biotechnology Limited’s market cap is €51.66M.
When is Avecho Biotechnology Limited’s upcoming earnings report date?
Avecho Biotechnology Limited’s upcoming earnings report date is Aug 31, 2026 which is in 48 days.
How were Avecho Biotechnology Limited’s earnings last quarter?
Avecho Biotechnology Limited released its earnings results on Feb 27, 2026. The company reported $0 earnings per share for the quarter, the consensus estimate of N/A by $0.
Is Avecho Biotechnology Limited overvalued?
According to Wall Street analysts Avecho Biotechnology Limited’s price is currently Overvalued.
Does Avecho Biotechnology Limited pay dividends?
Avecho Biotechnology Limited does not currently pay dividends.
What is Avecho Biotechnology Limited’s EPS estimate?
Avecho Biotechnology Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avecho Biotechnology Limited have?
Avecho Biotechnology Limited has 3,863,725,800 shares outstanding.
What happened to Avecho Biotechnology Limited’s price movement after its last earnings report?
Avecho Biotechnology Limited reported an EPS of $0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Avecho Biotechnology Limited?
Currently, no hedge funds are holding shares in DE:OEZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avecho Biotechnology Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-258.19%
Trailing 12-Months
Asset Growth
42.21%
Trailing 12-Months
Company Description
Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Imugene
―
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Prescient Therapeutics Limited
―
Recce Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---